

## Summary of NICE Guidelines

Title	Dapagliflozin in combination therapy for treating type 2 diabetes
NICE Reference	TA288
Date of Review:	July 2018
Date of Publication	June 2013
Summary of Guidance (Max 250 words)	<ul style="list-style-type: none"> <li>• Dapagliflozin inhibits glucose reabsorption in the kidneys to promote excretion of excess glucose. Therefore it can be used in patients with type 2 diabetes to improve glycaemic control.</li> <li>• Dapagliflozin, given in combination with metformin in a dual therapy regimen, is recommended as a treatment for type 2 diabetes when used as described for dipeptidyl peptidase-4 inhibitors in NICE clinical guidance 87.</li> <li>• Dapagliflozin, used alongside insulin with or without other antidiabetic drugs is also recommended for treatment of type 2 diabetes.</li> <li>• Use of dapagliflozin in combination with metformin and a sulfonylurea in a triple therapy regimen is not recommended for treatment of type 2 diabetes.</li> <li>• Patients that are already receiving dapagliflozin as part of a dual or triple therapy regimen, which is not recommended as above, should be able to continue this treatment until they and their clinician consider it appropriate to stop.</li> </ul>
Impact on Lab (See below)	■ None
Lab professionals to be made aware	Not applicable
Please detail the impact of this guideline (Max 150 words)	No impact on laboratory service.

### Impact on Lab

- **None:** This NICE guideline has no impact on the provision of laboratory services
- **Moderate:** This NICE guideline has information that is of relevance to our pathology service and may require review of our current service provision.
- **Important:** This NICE guideline is of direct relevance to our pathology service and will have a direct impact on one or more of the services that we currently offer.

**Written by: Chris Parker**

**Reviewed by: Professor Roy Sherwood**